Catalyst Event
Abbott Laboratories (ABT) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/28/2026, 12:00:00 AM
Received U.S. FDA clearance and CE Mark approval for its next-generation Ultreon 3.0 Software, an AI-powered coronary imaging platform.
Korean Translation
차세대 AI 기반 관상동맥 영상 플랫폼인 Ultreon 3.0 소프트웨어에 대해 미국 FDA 허가 및 CE 마크 승인을 획득함.
Related Recent Events
Lululemon Athletica Inc (LULU) · Earnings Release
Lululemon's Q1 2026 earnings release is scheduled for June 4, 2026, with analysts forecasting weak results following previous guidance. Earnings releases typically result in a >5% price impact, justifying a Medium importance, scheduled.
6/4/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Earnings Release
Medium importance is estimated due to the historical impact of quarterly earnings on stock volatility. Q1 2026 earnings release is scheduled.
5/27/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to announce its first quarter 2026 financial results. Low importance as it is a routine earnings call, scheduled.
5/6/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Earnings Release
Life Time is scheduled to release its Q1 2026 financial results before market open on May 5, 2026. Importance is Medium as earnings releases typically result in price movements exceeding 5%, scheduled.
5/5/2026, 12:00:00 AM
Amgen Inc (AMGN) · Earnings Release
Amgen is scheduled to report its first quarter 2026 financial results after the market close on April 30, 2026, followed by a conference call with management, scheduled. High importance is estimated due to typical volatility surrounding earnings releases.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026. This is a recurring event with high potential for stock price impact (analysts estimate ≥10%) based on revenue, earnings per share, and future guidance. scheduled
4/30/2026, 12:00:00 AM